Imaging Differentiation of Adrenal Adenoma, Carcinoma, and Pheochromocytoma
Use noncontrast CT attenuation as your first-line discriminator: adenomas typically show ≤10 HU, while carcinomas and pheochromocytomas both demonstrate >20 HU, with MRI chemical shift imaging and T2-weighted sequences providing critical secondary differentiation when CT is indeterminate. 1
Primary Imaging Approach: Noncontrast CT
Adenoma
- Attenuation ≤10 HU on noncontrast CT is diagnostic - these lesions contain intracellular lipid and require no further imaging regardless of size 1, 2
- Mean attenuation: 8 HU ± 18 3
- Homogeneous appearance
- Well-defined margins
Carcinoma (ACC)
- Attenuation typically >20 HU (mean 39 HU ± 14) 3
- Inhomogeneous/heterogeneous appearance 1, 2
- Size >4 cm with HU >20 has sufficiently high malignancy risk to warrant surgery 1, 2
- May show areas of hemorrhage or necrosis
- 91% of ACCs are >4 cm 1
Pheochromocytoma
- Attenuation >20 HU (mean 44 HU ± 11) 3
- Often heterogeneous with cystic/hemorrhagic areas
- Cannot be reliably differentiated from metastases on CT alone 1
Secondary Imaging: MRI Chemical Shift Imaging
When noncontrast CT shows attenuation 10-30 HU, proceed directly to MRI rather than contrast-enhanced CT 1
Adenoma
- Signal loss on opposed-phase vs in-phase sequences due to intracellular lipid 1
- This is the defining MRI feature
- CSI less effective when attenuation >30 HU 1
Carcinoma and Pheochromocytoma
- No signal loss on chemical shift imaging - absence of intracellular lipid 1
- Both lack the intracellular fat content seen in adenomas
Tertiary Imaging: T2-Weighted MRI
T2-weighted imaging is critical for distinguishing pheochromocytoma from carcinoma when both show high attenuation and no signal loss on CSI.
Pheochromocytoma
- Markedly hyperintense on T2-weighted sequences - this is the classic distinguishing feature 1
- T2W signal intensity ratio (nodule-to-muscle) has 91.4% sensitivity and 81.5% specificity (AUC 0.910) 4
- May show "light bulb" bright appearance
Carcinoma
- Variable T2 signal, typically less hyperintense than pheochromocytoma
- More heterogeneous with areas of necrosis/hemorrhage better delineated on MRI 1
Contrast Washout Analysis: Important Limitations
Recent evidence shows contrast washout is less reliable than previously thought and should NOT be your primary differentiator 1
Why Washout Fails
- Up to 35% of pheochromocytomas mimic adenoma washout characteristics (>60% relative washout) 1
- Certain metastases (renal, hepatocellular) also show adenoma-like washout 1
- Adenomas show >60% relative washout and >40% absolute washout at 10 minutes 3
- Carcinomas and pheochromocytomas show <50% absolute and <40% relative washout 3
However, these thresholds have significant overlap in clinical practice 1
Practical Algorithm
Start with noncontrast CT:
If attenuation 10-30 HU or indeterminate:
- Proceed to MRI with chemical shift imaging 1
- Signal loss on opposed-phase → Adenoma
- No signal loss → Proceed to T2-weighted imaging
T2-weighted MRI for lesions without signal loss:
Always perform biochemical testing for pheochromocytoma (plasma/urine metanephrines) before any intervention, even when imaging suggests other diagnoses 1, 5
Critical Pitfalls
- Never rely solely on contrast washout - it misses 35% of pheochromocytomas 1
- Size <4 cm does NOT exclude carcinoma - 9% of ACCs are <4 cm and should be discussed at multidisciplinary conference 1
- Heterogeneous adenomas can mimic carcinoma or pheochromocytoma, particularly when ≥4 cm 6
- Imaging cannot differentiate pheochromocytoma from metastasis - biochemical testing is mandatory 1
- Lipid-poor adenomas (10-30 HU) require MRI, not just contrast-enhanced CT 1
Special Populations
For patients <40 years or pregnant: use MRI preferentially to avoid radiation, with surgical consideration for any non-characteristically benign lesion 1